Comparison of different chemoradiotherapy methods for bone metastasis of non-small cell lung cancer
10.3760/cma.j.issn.0254-9026.2019.12.008
- VernacularTitle: 不同放化疗方式治疗非小细胞肺癌骨转移效果比较
- Author:
Wenbin PAN
1
;
Weiyue HE
Author Information
1. Department of Radiotherapy, Zhoushan Hospital, Zhejiang Province, Zhoushan 316000, China
- Publication Type:Journal Article
- Keywords:
Carcinoma, non-small cell lung;
Neoplasm metastasis;
Radiotherapy
- From:
Chinese Journal of Geriatrics
2019;38(12):1353-1356
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the clinical efficacy and safety of concurrent chemoradiotherapy and sequential chemoradiotherapy for bone metastasis of non-small cell lung cancer(NSCLC).
Methods:This was a retrospective cohort study, in which 120 patients with bone metastases from NSCLC admitted to our hospital from June 2013 to June 2018 were enrolled.Of these patients, 60 received sequential chemotheradiotherapy and 60 patients received concurrent chemoradiotherapy.Bone pain was measured before treatment, at 1-month, 2-months into treatment, and 1-month after treatment.Short-term efficacy and adverse reactions were compared between the two groups.
Results:There were no significant differences in pain relief rate at 1-month, 2-months into treatment and 1-month after treatment between the two groups(all P>0.05). Meanwhile, the objective response rate(50.0% vs.36.7%)and disease control rate(90.0% vs.83.3%)were also similar between the two groups(χ2=2.172, 1.154, P=0.141, 0.283). The incidences of toxic and side effects, including neutropenia(90.0% vs.60.0%), leukopenia(96.7% vs.63.3%)and nausea(50.0% vs.23.0%)were significantly higher in the concurrent chemoradiotherapy group than those in the sequential chemotherapy/radiotherapy group(all P<0.05). However, the rates of other toxic and side effects such as thrombocytopenia, vomiting, fatigue and alopecia were comparable between the two groups(all P>0.05).
Conclusions:Compared with sequential chemoradiotherapy, concurrent chemoradiotherapy has similar short-term efficacy in pain relief for bone metastasis of NSCLC, but the incidence of side effects is higher.
